Top 10 Pharma R&D Budgets in 2023 Save
Pharma budgets have undergone significant changes coming out of COVID. This year Merck & Co. has knocked Roche from previous years of leading in research and development (R&D) budgets and investments. In 2023 Merck invested a whopping $30 billion in R&D, nearly 51% of their 2023 total revenues..
Mercks $30.53 billion R&D far surpassed the $13.5 billion spent in 2022; with more than half spent on partnerships and acquisitions (Such is the case with many pharma R&D budgets)
Dollars budgeted for R&D, may be different than a the number programs funded by pharms. Leading the way in R&D pipeline programs is Pfizer (with 106), followed by AstraZeneca (104) and BMS (94).
The top 10 pharma R&D budgets for 2023 (based on adjusted and GAAP measures):
|
R&D Budget (billions) |
2023 Total Revenue (billions) | R&D % of Revenue | |
| Merck | $30.53 | $60.1 | 50.8% |
| J&J | $15.2 | $85.2 | 17.7% |
| Roche | $14.97 | $66.4 | 22.6% |
| Novartis | $11.37 | $45.4 | 25% |
| Astra Zeneca | $10.94 | $45.81 | 24% |
| Pfizer | $10.67 | $58.5 | 18.2% |
| Eli Lilly | $9.31 | $34.12 | 27% |
| BMS | $9.29 | $45 | 20.6% |
| AbbVie | $7.68 | $54.32 | 14.1% |
| Sanofi | $7.32 | $46.81 | 15.6% |
Continue Reading
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.